Komori
Share Issuance and Disposal4974TAKARA BIO INC.Materials and Chemicals

Notice Concerning the Approval Resolution for the Share Consolidation, Abolition of the Provisions on the Number of Shares Constituting One Unit, and Partial Amendments to the Articles of Incorporation

At an extraordinary general meeting of shareholders, the share consolidation of 15,332,374 shares into 1 share, the abolition of the share unit and the amendment to the Articles of Incorporation were approved. The total number of issued shares after the consolidation will be 6, and the Company is scheduled to be delisted on 12 June 2026.

Worth reading
37Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
15332374
Reverse stock split of shares into 1 share
Wording
Conditional
How definitive the wording is.

Details of issuance or disposal

Share consolidation

Stock Split Ratio15,332,374 shares consolidated into 1 share. The effective date is scheduled for 16 June 2026.
Procedures under the Corporate Code of Conduct
Approved at the extraordinary general meeting of shareholders held on 20 May 2026
Details of issuance or disposal
ItemDetails
Type of issuance or disposalShare consolidation
Total number of issued shares120,415,300 shares → 6 shares
Stock Split Ratio15,332,374 shares consolidated into 1 share. The effective date is scheduled for 16 June 2026.
Procedures under the Corporate Code of ConductApproved at the extraordinary general meeting of shareholders held on 20 May 2026
Items this document does not state (24)
Number of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyDilution RateBasis for determining the amount to be paidExercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To implement the transaction as part of a series of transactions aimed at taking the Company private with only the tender offeror as a shareholder.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning the Approval Resolution for the Share Consolidation, Abolition of the Provisions on the Number of Shares Constituting One Unit, and Partial Amendments to the Articles of Incorporation | TAKARA BIO INC. (4974) timely disclosure | Komori